ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.62
-0.37%
US Tech 100
20,874.00
-1.46%
S&P 500
6,025.99
-0.95%
US Dollar vs CAD
1.42965
-0.01%
Bitcoin
96,483.90
-0.06%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Vanda Pharmaceuticals Inc (VNDA) Share Price

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc (VNDA)

NASDAQ
4.80
0.11
(2.35%)
Closed February 08 3:00PM
Delayed by 15 minutes
4.80
-0.005
(-0.10%)
After Hours: 3:03PM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
4.80
Bid
4.62
Ask
4.93
Volume
934,019
4.65 Day's Range 4.83
3.61 52 Week Range 6.75
Market Cap
279.879M
Previous Close
4.69
Open
4.75
Last Trade
1
@
4.93
Last Trade Time
Financial Volume
US$ 4,455,633
VWAP
4.7704
Average Volume (3m)
600,660
Shares Outstanding
58,308,144
Dividend Yield
-
PE Ratio
111.63
Earnings Per Share (EPS)
0.04
Revenue
192.64M
Net Profit
2.51M

About Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder... Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include Tradipitant (VLY-686), VTR-297, and VQW-765. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.vandapharma.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Vanda Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VNDA. The last closing price for Vanda Pharmaceuticals was US$4.69. Over the last year, Vanda Pharmaceuticals shares have traded in a share price range of US$ 3.61 to US$ 6.75.

Vanda Pharmaceuticals currently has 58,308,144 shares outstanding. The market capitalization of Vanda Pharmaceuticals is US$273.47 million. Vanda Pharmaceuticals has a price to earnings ratio (PE ratio) of 111.63.

Ask ADVFN Intelligence (AI)

VNDA Latest News

More News

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

February 07 2025
Edgar (US Regulatory)

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025 PR Newswire WASHINGTON, Feb. 5, 2025 Conference Call and Webcast to Follow WASHINGTON...

February 05 2025
PR Newswire (US)

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

February 05 2025
Edgar (US Regulatory)

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular PsoriasisVanda expects to immediately begin preparing BLA and MAA applications for the US and EUAnaptys to...

February 03 2025
GlobeNewswire Inc.

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist PR Newswire WASHINGTON and SAN DIEGO, Feb...

February 03 2025
PR Newswire (US)

Form 8-K - Current report

January 27 2025
Edgar (US Regulatory)

Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis

Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis PR Newswire WASHINGTON, Jan. 27, 2025 Highlights faulty FDA reviewWASHINGTON...

January 27 2025
PR Newswire (US)

Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review

Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review PR Newswire WASHINGTON, Jan. 8, 2025 WASHINGTON, Jan. 8, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda...

January 08 2025
PR Newswire (US)

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera PR...

December 20 2024
PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities

November 18 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.2445.355575065854.5564.8054.2155108394.48633985CS
40.183.89610389614.624.8054.2155931204.45265684CS
12-0.32-6.255.125.424.2156006604.6955721CS
26-0.59-10.94619666055.395.5454.2156032114.84033835CS
521.0829.03225806453.726.753.6111691315.02352179CS
156-7.7-61.612.514.153.2958437076.04867281CS
260-8.66-64.33878157513.4621.86273.2957213988.43874815CS

VNDA - Frequently Asked Questions (FAQ)

What is the current Vanda Pharmaceuticals share price?
The current share price of Vanda Pharmaceuticals is US$ 4.80
How many Vanda Pharmaceuticals shares are in issue?
Vanda Pharmaceuticals has 58,308,144 shares in issue
What is the market cap of Vanda Pharmaceuticals?
The market capitalisation of Vanda Pharmaceuticals is USD 273.47M
What is the 1 year trading range for Vanda Pharmaceuticals share price?
Vanda Pharmaceuticals has traded in the range of US$ 3.61 to US$ 6.75 during the past year
What is the PE ratio of Vanda Pharmaceuticals?
The price to earnings ratio of Vanda Pharmaceuticals is 111.63
What is the cash to sales ratio of Vanda Pharmaceuticals?
The cash to sales ratio of Vanda Pharmaceuticals is 1.45
What is the reporting currency for Vanda Pharmaceuticals?
Vanda Pharmaceuticals reports financial results in USD
What is the latest annual turnover for Vanda Pharmaceuticals?
The latest annual turnover of Vanda Pharmaceuticals is USD 192.64M
What is the latest annual profit for Vanda Pharmaceuticals?
The latest annual profit of Vanda Pharmaceuticals is USD 2.51M
What is the registered address of Vanda Pharmaceuticals?
The registered address for Vanda Pharmaceuticals is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Vanda Pharmaceuticals website address?
The website address for Vanda Pharmaceuticals is www.vandapharma.com
Which industry sector does Vanda Pharmaceuticals operate in?
Vanda Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MGOLMGO Global Inc
US$ 0.4191
(126.54%)
780.46M
CDTConduit Pharmaceuticals Inc
US$ 2.831
(82.65%)
140.32M
GSIWGarden Stage Ltd
US$ 0.79
(78.73%)
215.16M
TOIIWOncology Institute Inc
US$ 0.033
(58.88%)
7.27k
CYTHCyclo Therapeutics Inc
US$ 1.19
(54.55%)
72.39M
FTELFitell Corporation
US$ 2.70
(-57.01%)
2.3M
SGBXSafe and Green Holdings Corporation
US$ 0.6401
(-44.82%)
5.65M
NKLANikola Corporation
US$ 0.4432
(-41.10%)
52.44M
PLRXPliant Therapeutics Inc
US$ 7.785
(-34.85%)
6.44M
LIPOLipella Pharmaceuticals Inc
US$ 3.08
(-33.76%)
2.2M
MGOLMGO Global Inc
US$ 0.4191
(126.54%)
780.46M
RIMEAlgorhythm Holdings Inc
US$ 0.0169
(-20.66%)
262.79M
GSIWGarden Stage Ltd
US$ 0.79
(78.73%)
215.16M
BHATBlue Hat Interactive Entertainment Technology
US$ 0.0537
(14.74%)
210.78M
NVDANVIDIA Corporation
US$ 129.84
(0.90%)
209.04M

VNDA Discussion

View Posts
eyeownu eyeownu 2 months ago
im a buyer at 5.07.nice triangle has formed. low float. plenty of cash on balance sheet. book value 9.20/sh
👍️0
Zilla Zilla 4 months ago
WOW talk about being lucky. Bought calls Friday for 2025 just in case something happens in 2024. Up 20% pre-market with an 8 all cash offer on the table.
👍️0
Monksdream Monksdream 5 months ago
VNDA under $7
👍️0
harry crumb harry crumb 7 months ago
Watching this closely
👍️0
Monksdream Monksdream 7 months ago
VNDA under $10
👍️0
Monksdream Monksdream 8 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
Monksdream Monksdream 8 months ago
Over $6
👍️0
tw0122 tw0122 8 months ago
Vanda acquired U.S. and Canadian rights to PONVORY® from a Johnson & Johnson Company on December 7, 2023. PONVORY® is approved by the U.S. Food and Drug Administration (FDA) and Health Canada to treat adults with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease (RMS).

In anticipation of the commercial launch of PONVORY® for RMS in the third quarter of 2024, Vanda is initiating a host of commercial activities including the creation of a specialty sales force, a prescriber awareness program and a comprehensive marketing program.
👍️0
harry crumb harry crumb 9 months ago
Gonna be a winner. Patience
👍️0
harry crumb harry crumb 9 months ago
Over 5$!
👍️0
Monksdream Monksdream 9 months ago
VNDA under $5
👍️0
harry crumb harry crumb 9 months ago
Let er rip $$$$$$$$
👍️0
Tiger Money Tiger Money 10 months ago
Agreed. This could double quickly
👍️0
philaya philaya 10 months ago
got this today...
very good trades.
👍️0
harry crumb harry crumb 10 months ago
This little gem could run up fast, they obviously have their science going in the right direction as the offers are there just not the price, could be a 10.00 offer in the works
👍️0
morokoy morokoy 10 months ago
Shares Outstanding 57,537,499 shares
Insider Shares 7,908,897 shares
Insider Ownership 13.75 %
Total Insiders 34
👍️0
morokoy morokoy 10 months ago
"The dividend distribution of rights will be payable to stockholders of record as of the close of business on April 29, 2024."

A shareholder may also receive distributions such as additional stock or stock rights in the distributing corporation; such distributions may or may not qualify as dividends.

A shareholder may also receive distributions such as additional stock or stock rights in the distributing corporation; such distributions may or may not qualify as dividends. You should receive a Form 1099-DIV, Dividends and Distributions from each payer for distributions of at least $10.

Guess we'll have to wait on the promised 8K.

Additional details of the Rights Plan will be contained in a Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC"). The filing will be available on the SEC's website at www.sec.gov.
👍️0
harry crumb harry crumb 10 months ago
Minimum 8$ imo
👍️0
MiamiGent MiamiGent 10 months ago
Vanda Pharmaceuticals rejects takeover proposal from Future Pak
REUTERS
1 mins ago
April 17 (Reuters) - Vanda Pharmaceuticals Inc (VNDA.NaE) on Wednesday said it is rejecting a takeover proposal from Future Pak, a privately-held contract manufacturer and packager of pharmaceuticals, as it significantly undervalues the company.

(Reporting by Sriparna Roy in Bengaluru; Editing by Tasim Zahid)
👍️0
Monksdream Monksdream 10 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc
👍️ 1
MiamiGent MiamiGent 10 months ago
Probably...but I took it at 5.49
👍️0
Monksdream Monksdream 10 months ago
Will it grow legs after 9:30
👍️0
MiamiGent MiamiGent 10 months ago
VNDA Vol picking up..

$5.49 +$1.44 (+35.56%)

Volume 3,354,569

90 DAV... 2M
👍️0
MiamiGent MiamiGent 10 months ago
VNDA Here we go
$5.3781 +$1.3281 (32.79%)

Bid ARCX
5.36 x 10
Ask XNMS
5.38 x 11
Volume
2,971,106
👍️0
MiamiGent MiamiGent 10 months ago
VNDA Vol is good. Already @ 90 DAV
Volume 2,056,421
10/90-day avg. volume
7M / 2M
👍️0
MiamiGent MiamiGent 10 months ago
VNDA Good post, Laster.
https://www.futurepak.com/
👍️0
Laster Laster 10 months ago
The major question is who is Future Pak really?
Is this a legit offer?
Either way, company is extremely undervalued with no debt (I believe) and lots of cash.
Large short position. Lots of selling PM at $5.
Market does not seem to believe this offer. Sorry.
👍️0
MiamiGent MiamiGent 10 months ago
VNDA Float 52.05M

Shares Short (3/28/2024) 2.49M
Short Ratio (3/28/2024) 2.78
Short % of Float (3/28/2024) 5.45%
👍️0
MiamiGent MiamiGent 10 months ago
VNDA
Bid EDGX
4.85 x 3
Ask EDGX
4.88 x 3

Volume
1,790,654
Avg Vol (10 day) 6.63M
👍️0
MiamiGent MiamiGent 10 months ago
Vanda Pharmaceuticals
Closed .01 (-0.25%)

Pre-market
$5.15 +1.10 (+27.16%)
As of Apr-17-2024 7:23:52 AM ET
Bid x size $5.14 x 1
Ask x size $5.16 x 3
👍️0
MiamiGent MiamiGent 10 months ago
VNDA In 5.12. Let's see, said the blind man.
👍️0
MiamiGent MiamiGent 10 months ago
Vanda Pharmaceuticals jumps 38% on Future Pak's latest buy offer
Apr. 17, 2024 6:41 AM ETVanda Pharmaceuticals Inc. (VNDA) Stock
👍️0
MiamiGent MiamiGent 10 months ago
What's the news?
👍️0
Awl416 Awl416 10 months ago
Damn
👍️0
Monksdream Monksdream 10 months ago
Will it grow legs after 9:30
👍️0
Monksdream Monksdream 10 months ago
Will it grow legs after 9:30
👍️0
tknuncle tknuncle 1 year ago
I have been acquiring since $3.90. I wish that I would have waited longer lol but, like what I see with VNDA. Was going to grab the last of my starter position soon. GLTA
👍️0
weedtrader420 weedtrader420 1 year ago
FDA Approve
👍️0
Triple nickle Triple nickle 1 year ago
Fda accepts new drug application for tradipitant in the after hours today
👍️ 1
jgrabar jgrabar 3 years ago
$VNDA -On May 19, 2022, Vanda Pharmaceuticals agreed to settle a securities fraud class action complaint (the “Complaint”) for $11.5 Million. https://grabarlaw.com/the-latest/vanda-pharmaceuticals-investigation/
👍️0
RNsidersbuying RNsidersbuying 4 years ago
VNDA 12.34 - FDA Approves HETLIOZ® (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome

https://ih.advfn.com/stock-market/NASDAQ/vanda-pharmaceuticals-VNDA/stock-news/83807075/fda-approves-hetlioz-tasimelteon-for-the-treatmen
👍️0
XenaLives XenaLives 5 years ago
Everything would be a lot better if the govt. would just let doctors treat COVID like another flu bug. The drama is getting old.
👍️0
Peepson Peepson 5 years ago
Yo, this thing is going to trade sideways for a while. They have a drug that could help with covid but so does every other pharma company. Its a safe hold imo but nothing will happen fast i don't think
👍️0
XenaLives XenaLives 5 years ago
What's up? Doesn't seem to be much interest. I was looking at the chart but haven't found much on the company yet.

👍️0
otcmoneydoubler otcmoneydoubler 5 years ago
LOL. VNDA GOT NEWS TODAY. SO WHAT DD HAVE YOU GOT TO SHARE?
👍️0
Peepson Peepson 5 years ago
Yo, does anyone still follow this board. I might have some interesting dd to share.
👍️0
bezen bezen 8 years ago
https://finance.yahoo.com/news/jefferies-5-top-biotech-stocks-133534894.html
👍️0
Coz Mabluda Coz Mabluda 8 years ago
Brett Jensen. SA article re VNDA. Expects positive analyst's review.

Vanda Pharmaceuticals (NASDAQ:VNDA) posted solid third quarter results on Thursday. Instead of losing a dime a share as expected, the company posted a profit of 11 cents a share. Revenue was also up more than 35% from the same period a year ago. The company now looks like it could be profitable in FY2017. I expect some positive analyst commentary on this name by analysts over the next week. Vanda has a solid pipeline and over $140 million in cash and marketable securities on the balance sheet. One has to like the company's growth trajectory and the concern seems undervalued with just a $600 million market capitalization.



👍️0
stocktrademan stocktrademan 8 years ago
fast and steady profit scan VNDA bullish 16.64



normal chart


log chart

👍️0
ClearlyStocks ClearlyStocks 8 years ago
VNDA $16.74
👍️0

Your Recent History

NASDAQ
VNDA
Vanda Pharmaceuticals
LSE
88DB
Roy.bk.can. 38
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads